

# ABSTRACT

This invention relates to novel arylamines which are antagonists of the melanin-concentrating hormone receptor 1 (MCH R1), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in medicines for the treatment of obesity, diabetes, depression, and/or anxiety. Compounds of the invention have the formula:

